# MODIFIED BINDING POLYPEPTIDES FOR OPTIMIZED DRUG CONJUGATION


## Abstract

Engineered antibodies that are stable and can be conjugated to a ligand or drug at a ligand/drug to antibody ratio of above 3, making these conjugates suitable for treatment of a variety of indications, are provided. Methods of producing these engineered antibodies are also provided. In a first embodiment, the antibody comprises a first engineered reactive amino acid residue at position 274 according to the numbering of the EU index of Kabat and a second engineered reactive amino acid residue at position 339, 360, 384, 385, 422 and/ or 440. In a second embodiment, the antibody comprises a first engineered reactive amino acid residue at position 339 according to the numbering of the EU index of Kabat and a second engineered reactive amino acid residue at position 290, 360, 384, 385, 422 and/or 440. In a third embodiment, the antibody comprises a first engineered reactive amino acid residue at position 118 according to the numbering of the EU index of Kabat and a second engineered reactive amino acid residue at position 274, 339, 384, 385, 422 and/or 440. In a fourth embodiment, the antibody comprises a first engineered reactive amino acid residue at position 384 according to the numbering of the EU index of Kabat and a second engineered reactive amino acid residue at position 118, 274, 290 and/or 339. In a preferred embodiment, the engineered reactive amino acid residue is cysteine.


[FIG. 1]